Oragenics | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.96.

EBIT: As of FY2025 Q3, the actual value is USD -3.185 M.

Segment Revenue

• The company did not generate any revenue for the three and nine months ended September 30, 2025, and 2024.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss was $3,066,589, compared to $2,462,870 for the same period in 2024, representing an increase of $603,719 or 24.51%.
• Total Operating Expenses: For the nine months ended September 30, 2025, total operating expenses were $6,864,202, compared to $7,203,383 for the same period in 2024, representing a decrease of $339,181 or 4.71%.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $6,410,975, compared to $6,579,029 for the same period in 2024.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $16,949,901, compared to $6,239,577 for the same period in 2024.

Unique Metrics

• Research and Development Expenses: For the nine months ended September 30, 2025, R&D expenses totaled $1.7 million, compared to $2.4 million for the same period in 2024, representing a decrease of $727,119 or 29.7%.
• General and Administrative Expenses: For the nine months ended September 30, 2025, G&A expenses totaled $5.1 million, compared to $4.8 million for the same period in 2024, representing an increase of $387,938 or 8.2%.

Future Outlook and Strategy

• Core Business Focus: The company plans to advance the ONP-002 program toward Phase II clinical trials and further IND-enabling work, with expected increases in R&D expenses as these activities commence.
• Non-Core Business: The company is exploring strategic opportunities through business development activities such as strategic alliances, licensing deals, and collaborations to enhance shareholder value.
• Priority: The company expects to incur substantial expenditures to further develop its neurology assets, including ONP-002, and may seek additional equity and debt financings to support these activities.